TABLE 1.
Effect of bezafibrate on plasma TG, glucose, and PPARα target gene expression in liver
| Group | Control | Bezafibrate |
| Body weight (g) | 43.97 ± 0.93 | 44.2 ± 0.59 |
| Food intake (g/day) | 4.09 ± 0.007 | 4.10 ± 0.006 |
| Plasma TG (mg/dl) | 172.11 ± 11.54 | 123.16 ± 7.45a |
| Plasma glucose (mg/dl) | 568.49 ± 33.10 | 349.95 ± 18.73b |
| Cpt1a (% of control) | 100.00 ± 9.91 | 136.56 ± 10.20a |
| Cpt1b (% of control) | 100.00 ± 18.27 | 2,778.23 ± 316.81b |
| Aco (% of control) | 100.00 ± 24.35 | 679.17 ± 95.81b |
Data are mean ± SEM (n = 5–7). Control: HFD; bezafibrate: 0.2% bezafibrate + HFD.
a
P < 0.05, versus control.
b
P < 0.001 versus control.